LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Aandelen Lijst・Design Therapeutics Inc
Search

Design Therapeutics Inc

Gesloten

10.7 1.42

Strong Buy

Prijsupdate 10 jun 2026, 19:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.16

Max

11.1

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.6M

-18M

EPS

-0.29

Werknemers

54

EBITDA

-1.5M

-20M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+85.78% upside

Dividenden

By Dow Jones

Volgende Winsten

5 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-135M

665M

Vorige openingsprijs

9.28

Vorige sluitingsprijs

10.7

Design Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 jun 2026, 23:36 UTC

Winsten

Correction to Oracle Reports Higher 4Q Profit Article

DJ

Lezen

10 jun 2026, 23:19 UTC

Populaire aandelen

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

DJ

Lezen

10 jun 2026, 23:09 UTC

Belangrijke Marktbewegers

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

DJ

Lezen

10 jun 2026, 23:04 UTC

Winsten

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

DJ

Lezen

10 jun 2026, 20:44 UTC

Belangrijke Marktbewegers

Caterpillar Raises Quarterly Dividend 8%

DJ

Lezen

10 jun 2026, 23:49 UTC

Acquisities, Fusies, Overnames

Elliott: Northern Star Should Take No Options Off The Table

DJ

Lezen

10 jun 2026, 23:48 UTC

Acquisities, Fusies, Overnames

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

DJ

Lezen

10 jun 2026, 23:48 UTC

Acquisities, Fusies, Overnames

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

DJ

Lezen

10 jun 2026, 23:47 UTC

Marktinformatie

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

DJ

Lezen

10 jun 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

DJ

Lezen

10 jun 2026, 23:46 UTC

Acquisities, Fusies, Overnames

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

DJ

Lezen

10 jun 2026, 23:38 UTC

Marktinformatie

Global Equities Roundup: Market Talk

DJ

Lezen

10 jun 2026, 23:38 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

10 jun 2026, 23:38 UTC

Marktinformatie

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

DJ

Lezen

10 jun 2026, 23:32 UTC

Marktinformatie

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

DJ

Lezen

10 jun 2026, 23:20 UTC

Marktinformatie

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

DJ

Lezen

10 jun 2026, 22:05 UTC

Marktinformatie

Correction to Bank of Canada Stays on Hold Market Talk

DJ

Lezen

10 jun 2026, 21:57 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Lezen

10 jun 2026, 21:52 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Lezen

10 jun 2026, 21:35 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Lezen

10 jun 2026, 21:22 UTC

Winsten

Oracle Stock Slides on Increased Capital Spending -- WSJ

DJ

Lezen

10 jun 2026, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:39 UTC

Marktinformatie
Winsten

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

DJ

Lezen

10 jun 2026, 20:34 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Lezen

10 jun 2026, 20:33 UTC

Winsten

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

DJ

Lezen

10 jun 2026, 20:33 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:33 UTC

Marktinformatie
Winsten

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

DJ

Lezen

Peer Vergelijking

Prijswijziging

Design Therapeutics Inc Prognose

Koersdoel

By TipRanks

85.78% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 19.6 USD  85.78%

Hoogste 22 USD

Laagste 15 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Design Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Design Therapeutics Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

1,136.41

↓-0.5%

JNJ

Johnson and Johnson

238.85

↑ +0.91%

ABBV

AbbVie Inc

225.29

↑ +0.05%

UNH

UnitedHealth Group Inc

407.06

↓-1.28%

MRK

Merck & Co Inc.

119

↓-0.38%
help-icon Live chat